Trials / Completed
CompletedNCT04567667
Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants
Pharmacokinetics and Metabolism of [14C] BMS-986278 in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986278 as well as the safety and tolerability of BMS-986278 in healthy male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C] BMS-986278 | Specified dose on specified days |
| DRUG | Kinevac® | Specified dose on specified days |
Timeline
- Start date
- 2020-10-15
- Primary completion
- 2021-04-11
- Completion
- 2021-04-11
- First posted
- 2020-09-28
- Last updated
- 2022-06-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04567667. Inclusion in this directory is not an endorsement.